Lifecore Biomedical financials
$6.59+1.07%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q1 '27 Jun 30 | Q4 '26 Mar 31 | Q2 '26 Sep 30 | Q1 '25 May 25 | Q3 '25 Feb 23 | Q2 '25 Aug 25 | Q4 '24 May 26 | Q3 '24 Feb 25 | Q2 '24 Nov 26 | Q1 '24 Aug 27 | Q4 '23 May 28 | Q3 '23 Feb 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $34.2M | $23.2M | $31.1M | $36.4M | $35.2M | $24.7M | $37.9M | $35.7M | $30.1M | $24.5M | $31.1M | $26.5M |
| Gross profit | $12.1M | $4.5M | $7.8M | $14.0M | $9.8M | $5.4M | $17.3M | $11.9M | $10.0M | $2.7M | $7.8M | $8.5M |
| Gross margin | 35.3% | 19.2% | 25.0% | 38.4% | 28.0% | 21.8% | 45.6% | 33.3% | 33.0% | 11.1% | 25.0% | 32.2% |
| Operating income | $2.6M | -$4.7M | -$3.1M | $5.4M | -$2.2M | -$11.6M | $2.1M | -$895.0K | -$1.5M | -$8.6M | -$6.6M | -$6.5M |
| Net income | -$7.1M | -$15.9M | -$10.9M | -$2.0M | -$17.4M | -$16.2M | -$7.1M | $15.6M | $14.2M | -$10.8M | -$39.3M | -$36.5M |
| Net margin | −20.9% | −68.7% | −35.1% | −5.6% | −49.4% | −65.7% | −18.7% | 43.8% | 47.2% | −43.9% | −126.1% | −137.6% |
| Diluted EPS | $-0.19 | $-0.43 | $-0.29 | $-0.06 | $-0.47 | $-0.53 | $-0.16 | $0.42 | $0.39 | $-0.35 | $-1.30 | $-1.20 |
| EBITDA | $2.6M | -$2.4M | -$1.1M | $2.9M | -$217.0K | -$9.6M | $4.9M | $1.9M | $283.0K | -$6.4M | -$4.0M | -$752.0K |
| Operating cash flow | — | $4.7M | $1.8M | $5.3M | $1.2M | -$643.0K | $8.7M | -$1.4M | $1.3M | -$8.3M | -$2.3M | -$11.7M |
| Free cash flow | — | $3.6M | $25.0K | $3.3M | -$4.3M | -$4.0M | $6.0M | -$7.8M | -$3.0M | -$13.4M | -$9.4M | -$18.8M |
| Diluted shares | 37.6M | 37.5M | 37.4M | 37.0M | 37.0M | 30.9M | 43.2M | 36.6M | 36.4M | 30.4M | 30.3M | 30.3M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | May 25 | Feb 23 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $17.2M | $20.8M | $17.5M | $18.9M | $8.3M | $5.4M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $154.1M | $5.6M | $141.3M | $5.7M | $5.8M | $8.3M |
| Total assets | $229.5M | $225.5M | $232.2M | $235.2M | $239.3M | $237.7M |
| Total liabilities | $213.4M | $204.7M | $198.1M | $198.4M | $191.9M | $190.3M |
| Shareholders' equity | -$34.1M | -$28.4M | -$14.2M | -$10.5M | $1.3M | $2.2M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology